Chronic kidney disease (CKD) is defined as a progressive loss of renal function that lasts for more than 3 months, and is classified according to the degree of kidney damage – measured by the le ...
Cystatin C is emphasized as a preferred biomarker for accurate GFR measurement in CKD assessment. SGLT2i are recommended for CKD patients, regardless of diabetes status, for kidney and ...
Updates on chronic kidney disease (CKD) diagnosis, use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors as first-line therapy, and personalized treatment approaches for kidney and ...
Considering taking supplements to treat chronic kidney disease ckd? Below is a list of common natural remedies used to treat or reduce the symptoms of chronic kidney disease ckd. Follow the links ...
Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...
Assessment of proteinuria in addition to estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD) may help identify individuals at high risk of adverse outcomes ...
Chronic Kidney Disease (CKD) indicates prolonged kidney damage over three months, often undetectable until significant harm occurs. Key risk factors include diabetes, high blood pressure ...
GlobalData on MSN14d
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKDThe Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients, including those with nephrotic ...
Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback